Stocksigma LogoStocksigma Logo

Kilitch Drugs India Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

■ Revenue: 5,022 (+2.6% YoY | +11.9% QoQ) ■ EBITDA: 668 (+32.6% YoY | +127.6% QoQ) ■ EBITDA Margin (%): 13.3 (+300 bps YoY | +677 bps QoQ) ■ PAT: 223

Kilitch Drugs India Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

Kilitch Drugs India Ltd · Outcome · 07 Nov 2026, 2:19 am

Kilitch Drugs India Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 5,022 (+2.6% YoY | +11.9% QoQ) ■ EBITDA: 668 (+32.6% YoY | +127.6% QoQ) ■ EBITDA Margin (%): 13.3 (+300 bps YoY | +677 bps QoQ) ■ PAT: 223 (-72.8% YoY | -23.5% QoQ) ■ EPS (INR): 0.64 (-74.3% YoY | -22.9% QoQ)

Original exchange filing (PDF)

More announcements from Kilitch Drugs India Ltd

All Kilitch Drugs India Ltd announcements